| 发明名称 |
NOVEL ANTITUMORAL USE OF CABAZITAXEL |
| 摘要 |
The invention relates to a compound of formula:;;which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment. |
| 申请公布号 |
US2015118182(A1) |
申请公布日期 |
2015.04.30 |
| 申请号 |
US201414575578 |
申请日期 |
2014.12.18 |
| 申请人 |
Aventis Pharma S.A. |
发明人 |
GUPTA Sunil |
| 分类号 |
A61K31/337;A61K38/19 |
主分类号 |
A61K31/337 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of reducing the risk of neutropenia complications in a patient with prostate cancer being treated a compound of formula:which may be in base form or in the form of a hydrate or a solvate;comprising monitoring blood counts in the patient at regular intervals during treatment of the patient; reducing the dose of the compound if the patient experiences febrile neutropenia or prolonged neutropenia; discontinuing the treatment if the patient's neutrophil count is ≦1,500 cells/mm3; and optionally restarting the treatment when the patient's neutrophil counts recover to a level ≧1,500 cells/mm3. |
| 地址 |
Antony FR |
